- Home
- ICLR vs OWL Comparison
ICLR vs OWL Comparison
Compare ICLR & OWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICLR | OWL |
|---|---|---|
| Founded | 1990 | 2020 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 9.4B |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | ICLR | OWL |
|---|---|---|
| Price | $186.40 | $15.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $201.23 | $22.13 |
| AVG Volume (30 Days) | 1.0M | ★ 15.8M |
| Earning Date | 10-22-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 5.77% |
| EPS Growth | N/A | ★ 47.85 |
| EPS | ★ 7.47 | 0.08 |
| Revenue | ★ $8,102,602,000.00 | $2,745,943,000.00 |
| Revenue This Year | N/A | $18.06 |
| Revenue Next Year | $0.76 | $19.63 |
| P/E Ratio | ★ $25.41 | $201.13 |
| Revenue Growth | N/A | ★ 27.24 |
| 52 Week Low | $125.10 | $13.25 |
| 52 Week High | $228.29 | $26.73 |
Technical Indicators
Market Signals| Indicator | ICLR | OWL |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 50.20 |
| Support Level | $178.80 | $15.87 |
| Resistance Level | $188.99 | $17.00 |
| Average True Range (ATR) | 7.59 | 0.53 |
| MACD | 1.34 | 0.19 |
| Stochastic Oscillator | 83.07 | 55.18 |
Price Performance
Historical ComparisonAbout ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About OWL Blue Owl Capital Inc.
Blue Owl Capital is one of the world's largest alternative-asset managers, $295.6 billion in total managed assets, including $183.8 billion in fee-earning AUM, at the end of September 2025. The company has three core business segments: global private equity, (with $68.8 billion in total AUM and $40.2 billion in fee-earning AUM), private credit ($152.1 billion/$97.3 billion), and real estate/real assets ($74.7 billion/$46.3 billion). The firm primarily serves institutional investors (68% of AUM) and high-net-worth individuals (32%). The firm operates through more than 20 offices in the Americas, and the EMEA and Asia-Pacific regions.